Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment entities : Alnylam pharmaceuticals, inc. save search
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: 2023-10-09 (Crawled : 14:30) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -4.06%
H: 2.17%
C: -0.83%
fda drug treatment application response
Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: 2023-09-13 (Crawled : 22:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.8%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.99%
H: 0.0%
C: 0.0%
fda positive treatment meeting
Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: 2023-09-13 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.8%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.99%
H: 0.0%
C: 0.0%
fda drug review treatment application
Advancements in Diagnosis and Treatment Fuel Rising Prevalence of Thalassemia, Driving Market to 2028
Published: 2023-08-25 (Crawled : 03:00) - prnewswire.com
GLAXF | News | $20.305 -14.18% 630
|
Health Technology
|
| O: 2.25%
H: 0.0%
C: 0.0%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: 0.67%
H: 0.37%
C: 0.26%
GSK | News | $41.24 1.6% 0.0% 2.3M
|
Health Technology
|
| O: 0.67%
H: 0.45%
C: 0.2%
SGMO | News | $0.5212 2.18% 2.13% 2.3M
|
Health Technology
|
| O: -3.19%
H: 0.0%
C: 0.0%
IONS | $41.85 1.9% 1.86% 630K
|
Health Technology
|
| O: 0.0%
H: 1.68%
C: 1.28%
EDIT | News | $5.465 -2.41% -2.47% 1.6M
|
Health Technology
|
| O: 0.11%
H: 1.25%
C: -0.57%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -0.12%
H: 2.12%
C: 1.45%
treatment market
Agios Announces Exclusive Worldwide License Agreement for Novel siRNA for the Potential Treatment of Polycythemia Vera
Published: 2023-08-03 (Crawled : 11:00) - globenewswire.com
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -1.35%
H: 5.58%
C: 4.38%
AGIO | $31.82 5.33% 5.06% 1.2M
|
Health Technology
|
| O: -2.4%
H: 5.98%
C: 2.81%
license treatment potential agreement
Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk
Published: 2023-07-24 (Crawled : 06:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.88%
H: 0.0%
C: 0.0%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 0.06%
H: 0.0%
C: 0.0%
partnership treatment risk hypertension roche cardiovascular
Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: 2023-06-30 (Crawled : 14:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.94%
H: 0.0%
C: 0.0%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 1.45%
H: 1.03%
C: -2.01%
onpattro fda treatment meeting
Pozelimab (C5 Antibody) BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority Review
Published: 2023-02-21 (Crawled : 15:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.79%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: -0.09%
H: 0.59%
C: -0.21%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -2.68%
H: 0.6%
C: -7.83%
treatment fda disease children review
Alnylam Announces U.S. Food and Drug Administration (FDA) Acceptance of Supplemental New Drug Application for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: 2023-02-21 (Crawled : 14:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.79%
H: 0.0%
C: 0.0%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -2.68%
H: 0.6%
C: -7.83%
onpattro treatment drug application food
Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes
Published: 2022-12-21 (Crawled : 13:20) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 6.05%
H: 2.65%
C: 0.66%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 2.63%
H: 0.0%
C: 0.0%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -0.05%
H: 2.34%
C: 1.64%
treatment application diabetes
Alnylam Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: 2022-12-08 (Crawled : 22:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.5%
H: 0.16%
C: 0.16%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -1.32%
H: 0.0%
C: 0.0%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 0.43%
H: 3.16%
C: 2.44%
onpattro treatment drug application food
Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus Infection
Published: 2022-09-22 (Crawled : 13:20) - biospace.com/
VIR | $8.13 0.37% 0.37% 770K
|
Health Technology
|
| O: -1.55%
H: 2.68%
C: 1.2%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -0.53%
H: 0.0%
C: -1.26%
vir-2218 treatment hepatitis vir-3434 virus trial infection phase 2
Alnylam Receives Approval in Europe for AMVUTTRA® (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy
Published: 2022-09-20 (Crawled : 12:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -1.18%
H: 0.0%
C: 0.0%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 0.0%
H: 1.68%
C: -1.85%
amvuttra treatment europe approval
Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
Published: 2022-08-29 (Crawled : 13:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -1.08%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: -0.64%
H: 1.24%
C: 0.07%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -0.56%
H: 1.41%
C: -0.34%
treatment nephropathy positive study phase 2
Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
Published: 2022-06-14 (Crawled : 07:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -1.73%
H: 0.0%
C: 0.0%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 0.77%
H: 6.48%
C: 3.71%
treatment fda approval
Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
Published: 2022-06-09 (Crawled : 12:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.88%
H: 0.0%
C: 0.0%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 1.59%
H: 0.68%
C: -2.46%
treatment nephropathy topline positive phase 2
The Worldwide Paroxysmal Nocturnal Hemoglobinuria Treatment Industry is Expected to Reach $4.7 Billion by 2027
Published: 2022-03-23 (Crawled : 13:30) - prnewswire.com
TMO | News | $574.59 4.78% -1.12% 2.5M
|
Health Technology
|
| O: -1.66%
H: 0.0%
C: 0.0%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: 0.0%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.38%
H: 0.0%
C: 0.0%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -0.59%
H: 1.0%
C: -0.32%
treatment
Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1
Published: 2022-03-01 (Crawled : 16:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -3.33%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -1.3%
H: 0.0%
C: 0.0%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 0.65%
H: 3.47%
C: 2.28%
oxlumo new drug treatment application drug food
Soleo Health to Administer OXLUMO™ for the Treatment of Primary Hyperoxaluria Type 1
Published: 2022-01-11 (Crawled : 15:00) - biospace.com/
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -0.31%
H: 0.0%
C: 0.0%
treatment
Alnylam Submits CTA Application for ALN-APP, an Investigational RNAi Therapeutic for the Treatment of Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2021-12-22 (Crawled : 13:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.59%
H: 1.12%
C: 0.93%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -5.24%
H: 2.44%
C: -0.93%
alzheimer treatment application disease alzheimer’s alzheimer's disease alzheimer's
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.